Medexus Pharmaceuticals Inc.
MEDXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $25 | $25 | $25 | $30 |
| % Growth | 0.5% | -0.6% | -17.5% | – |
| Cost of Goods Sold | $11 | $11 | $12 | $15 |
| Gross Profit | $14 | $14 | $12 | $15 |
| % Margin | 55.7% | 56% | 50.2% | 50.7% |
| R&D Expenses | $2 | $2 | $3 | $2 |
| G&A Expenses | $8 | $8 | $9 | $7 |
| SG&A Expenses | $10 | $10 | $10 | $9 |
| Sales & Mktg Exp. | $2 | $2 | $1 | $3 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $12 | $13 | $14 | $11 |
| Operating Income | $1 | $1 | -$1 | $4 |
| % Margin | 5.6% | 3.5% | -4.7% | 12.6% |
| Other Income/Exp. Net | -$2 | -$0 | $0 | -$3 |
| Pre-Tax Income | -$0 | $1 | -$1 | $1 |
| Tax Expense | -$0 | $0 | -$0 | $0 |
| Net Income | -$0 | $1 | -$1 | $1 |
| % Margin | -1.3% | 2.1% | -2.2% | 2.4% |
| EPS | -0.01 | 0.016 | -0.02 | 0.03 |
| % Growth | -159.3% | 181.4% | -167% | – |
| EPS Diluted | -0.01 | 0.016 | -0.02 | 0.03 |
| Weighted Avg Shares Out | 32 | 32 | 28 | 25 |
| Weighted Avg Shares Out Dil | 32 | 32 | 28 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $2 | $2 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | $4 | $4 | $4 | $5 |
| % Margin | 14.2% | 18.1% | 14.9% | 15.4% |